MX2020004048A - Formas cristalinas de lenalidomida. - Google Patents

Formas cristalinas de lenalidomida.

Info

Publication number
MX2020004048A
MX2020004048A MX2020004048A MX2020004048A MX2020004048A MX 2020004048 A MX2020004048 A MX 2020004048A MX 2020004048 A MX2020004048 A MX 2020004048A MX 2020004048 A MX2020004048 A MX 2020004048A MX 2020004048 A MX2020004048 A MX 2020004048A
Authority
MX
Mexico
Prior art keywords
lenalidomide
crystalline forms
crystalline
forms
empty
Prior art date
Application number
MX2020004048A
Other languages
English (en)
Inventor
Venkata Raghavendracharyulu Palle
Ramakrishna Parameshwar Bhat
Lankeswararao Matti
Vijaybhaskar Reddy Regalla
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2020004048A publication Critical patent/MX2020004048A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona co-cristales novedosos de lenalidomida. La presente invención particularmente proporciona co-cristales novedosos de lenalidomida con resorcinol, metilparabeno y sacarina. La presente invención también proporciona los procesos para la producción de co-cristales de lenalidomida con resorcinol, metilparabeno y sacarina. La presente invención proporciona además procesos para la preparación de lenalidomida anhidra cristalina forma IV.
MX2020004048A 2017-09-27 2018-09-27 Formas cristalinas de lenalidomida. MX2020004048A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741034364 2017-09-27
PCT/IB2018/057500 WO2019064222A1 (en) 2017-09-27 2018-09-27 CRYSTALLINE FORMS OF LENALIDOMIDE

Publications (1)

Publication Number Publication Date
MX2020004048A true MX2020004048A (es) 2020-07-20

Family

ID=65901039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004048A MX2020004048A (es) 2017-09-27 2018-09-27 Formas cristalinas de lenalidomida.

Country Status (10)

Country Link
US (2) US11203585B2 (es)
EP (1) EP3687987A4 (es)
JP (1) JP2020535192A (es)
KR (1) KR20200092945A (es)
AU (1) AU2018343244A1 (es)
BR (1) BR112020006051A2 (es)
CA (1) CA3076986A1 (es)
MX (1) MX2020004048A (es)
RU (1) RU2020114885A (es)
WO (1) WO2019064222A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022036291A1 (en) * 2020-08-14 2022-02-17 Board Of Regents, The University Of Texas System Method of producing pharmaceutical cocrystals for additive manufacturing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2487215T3 (es) * 2009-03-02 2014-08-20 Generics [Uk] Limited Proceso mejorado
ES2727667T3 (es) * 2011-03-23 2019-10-17 Hetero Research Foundation Polimorfos de lenalidomida
CA2842316A1 (en) * 2011-07-19 2013-01-24 Amplio Pharma, Llc Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)­piperidine-2,6-dione
WO2014160686A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
US9695146B2 (en) * 2013-03-26 2017-07-04 Celgene Corporation Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof
WO2016026785A1 (en) * 2014-08-19 2016-02-25 Synthon B.V. Process for making crystalline form a of lenalidomide

Also Published As

Publication number Publication date
CA3076986A1 (en) 2019-04-04
KR20200092945A (ko) 2020-08-04
WO2019064222A1 (en) 2019-04-04
US20200347027A1 (en) 2020-11-05
US11203585B2 (en) 2021-12-21
AU2018343244A2 (en) 2020-06-04
RU2020114885A (ru) 2021-10-27
US20210163442A1 (en) 2021-06-03
AU2018343244A1 (en) 2020-05-14
EP3687987A1 (en) 2020-08-05
JP2020535192A (ja) 2020-12-03
EP3687987A4 (en) 2021-03-24
BR112020006051A2 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
MX2020004287A (es) Procesamiento de biomasa.
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
GEP20227403B (en) Compounds
IL269196A (en) New inhibitors
MX2020003421A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2020003760A (es) Formulaciones de niraparib.
IN2015DE00625A (es)
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020004424A (es) Formulacion aerosolizable.
MX2020003754A (es) Metodo de formacion de elementos de microimagen.
LT3599836T (lt) Tiektuvas
MX2020003617A (es) Dispositivo de preparacion de cables.
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
ZA201907529B (en) Feeder
MX2020003578A (es) Sal de edaravone.
MX2020004245A (es) Estabilizador mejorado para poliamidas.
MX2020004272A (es) Cartucho configurado para formar una parte de una pezonera y una pezonera.
MX2020004048A (es) Formas cristalinas de lenalidomida.
GB2612702B (en) Host-biome interactions
MX2020003440A (es) Red de seguridad.
MX2018009818A (es) Formulacion y elaboracion de una pasta alimenticia con harina de trigo y hongo comestible.
MX2018009437A (es) Sistema de prevención de perdida de dispositivos electrónicos móviles en tiempo real.
MX2020004664A (es) Dispositivo generador de humo mejorado.
MX2020003539A (es) Dispositivo de impulso.
MX2020003703A (es) Composiciones de sabor.